AKRO241115C35000
- 1.60
- +0.08+5.26%
Akero Therapeutics Newsroom
HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target
H.C. Wainwright Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $50
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46
Akero Therapeutics' Promising Phase 3 Programs Bolster Buy Rating
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46
Akero Therapeutics (AKRO) Receives a Buy From Morgan Stanley
Akero Therapeutics (AKRO) Gets a Buy From Evercore ISI
Akero Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Charles River Labs (CRL) and Akero Therapeutics (AKRO)
Buy Rating Affirmed on Akero Therapeutics Amid Promising EFX Trials and Robust Financial Outlook
Buy Rating for Akero Therapeutics Backed by Strong Financials and Promising Trial Outcomes
Akero Therapeutics Analyst Ratings
Akero Therapeutics Analyst Ratings
Wolfe Research Initiates Coverage on Akero Therapeutics With Outperform Rating, $40 Price Target
Akero Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target
Evercore ISI Group: Maintaining the Akero Therapeutics (AKRO.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $50.00 to $38.00.
Akero Therapeutics Analyst Ratings
Evercore ISI Group Maintains Outperform on Akero Therapeutics, Lowers Price Target to $38